Copyright
©The Author(s) 2020.
World J Clin Oncol. Jun 24, 2020; 11(6): 389-396
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.389
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.389
Diagnosis | Total | Percent (%) |
Giant cell tumor of bone | 7 | 20 |
Undifferentiated pleomorphic sarcoma | 4 | 11 |
Soft tissue leiomyosarcoma | 3 | 9 |
Liposarcoma | 3 | 9 |
Extremity synovial sarcoma | 3 | 9 |
Chondrosarcoma | 3 | 9 |
Desmoid | 3 | 9 |
High grade soft tissue sarcoma | 2 | 6 |
Scalp soft tissue sarcoma | 2 | 6 |
Low grade soft tissue sarcoma | 2 | 6 |
Angiosarcoma | 1 | 3 |
Myxofibrosarcoma | 1 | 3 |
Epithelioid sarcoma | 1 | 3 |
NCCN guidelines used | ||
STS extremity guidelines | 18 | 51 |
Bone: GCT of bone guidelines | 7 | 20 |
Bone: Chondrosarcoma guidelines | 3 | 9 |
STS head guidelines | 2 | 6 |
STS desmoid | 3 | 9 |
STS trunk guidelines | 2 | 6 |
TNM staging | ||
IA | 3 | 9 |
IB | 4 | 11 |
IIA | 3 | 9 |
IIB | 5 | 14 |
III | 4 | 11 |
IV | 5 | 14 |
IVA | 1 | 3 |
No staging necessary | 10 | 29 |
- Citation: Blank AT, Larson BM, Shaw S, Wakefield CJ, King T, Jones KB, Randall RL. National Comprehensive Cancer Network guidelines compliance of a sarcoma service: A retrospective review. World J Clin Oncol 2020; 11(6): 389-396
- URL: https://www.wjgnet.com/2218-4333/full/v11/i6/389.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i6.389